Cardium Therapeutics has achieved access to commercial development rights for certain new supramacromolecular polymer complexes enabling regulatable and localised topical delivery of nitric oxide (NO) for prolonged periods of one to three weeks to expand wound healing and tissue regeneration portfolio.
The new polymer-based technology represents a practical way to integrate the use of NO into a variety of wound healing products, which could include granulated and powder dressings, topical creams and gels, thin films and aqueous formulations, as well as electrospun fibers for dressings and bandages.
Cardium said that from a clinical development perspective, inhalable NO formulations have been approved for therapeutic use and the polymer components covered by this technology are currently used in FDA regulated medical products.
Cardium believes that this array of NO formulations offers the potential to commercially develop wound dressings and therapeutics that could be applied to acute as well as chronic wound care settings.
Cardium chairman and CEO Christopher Reinhard said that they were excited about the potential for the commercial development of NO therapy initiative for wound healing and tissue regeneration.
“It opens the door for us to develop product extensions based on our formulated collagen product platform and to develop new products for other wound healing applications and in other medical settings that could include acute applications for military and emergency medical services,” Reinhard said.
“Previous efforts to use NO as a therapeutic agent have been limited by the short duration of its release and short half-life in the body, as well as by the intrinsic instability of traditional NO delivery agents.
“This new and proprietary polymer-based technology allows for the localised delivery, activation and regulated release of NO over a period of time from one to several weeks, potentially enabling a new class of advanced wound therapeutics and dressings for both acute and chronic applications.”